Walleye Capital LLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $77,332 - $116,796	400 Added 80.0%	900 $252,000
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $85,685 - $141,615	500 New	500 $133,000
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $92,424 - $122,832	400 New	400 $96,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $106,816 - $149,584	-1,600 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $252,840 - $355,500	-3,000 Reduced 65.22%	1,600 $146,000
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $1.23 Million - $1.56 Million	-14,600 Reduced 76.04%	4,600 $397,000
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $1.69 Million - $2.64 Million	18,500 Added 2642.86%	19,200 $2.01 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $72,436 - $100,688	700 New	700 $88,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.